Breast Cancer Clinical Trials

Showing 2721-2740 of 4,817 trials

Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System

NCT02426489

The purpose of the study is to assess whether the addition of positron emission mammography will add diagnostic value to magnetic resonance imaging of the breast, in patients with lesions of the breast that are suspicious enough to warrant biopsy, or which have been confirmed as containing cancer cells.

Breast Cancer

Weinberg Medical Physics LLC1 participantsStarted Jul 2015

Not Yet Recruiting

SEMA4C as a Relapse Biomarker in Breast Cancer

NCT03663153

Breast cancer remains the most common cancer in women worldwide. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The objective of this study is to investigate SEMA4C's potential role as an early relapse biomarker in breast cancer.

Breast Cancer

Tongji Hospital4,200 participantsStarted Sep 2022

COMPLETED

RWD Study in HER2+ mBC Patients in Third-Line Therapy

NCT04566458

This retrospective observational study will collect Canadian real-world data (RWD) from HER2+ metastatic breast cancer (mBC) patients to describe treatment sequences of all therapies received in the metastatic setting, to measure overall survival (OS), progression free survival (PFS), time to next active anti-cancer therapy, and to estimate the health resources utilization (HRU) during third-line therapy.

Breast Cancer Stage IV

Exactis Innovation63 participantsStarted Oct 2020

Moncton, New Brunswick, Canada • Moncton, New Brunswick, Canada • Ottawa, Ontario, Canada +5 more locations

Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System

SEMA4C as a Relapse Biomarker in Breast Cancer

RWD Study in HER2+ mBC Patients in Third-Line Therapy

Related Searches

Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3

Proton Accelerated Partial Breast Irradiation

NSABP Biospecimen Discovery Project

Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer

Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Neoadjuvant GW572016 to Treat Breast Cancer

A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer